Overall, current treatment options for patient with advanced GIST progressing on imatinib are limited by two issues: first, the emergence of resistance mutations in the ATP pocket and in the activation loop of KIT and second, a poor kinome selectivity of second-generation kinase inhibitors resulting in unfavorable safety profiles and leading to dose modifications and drug holidays (20, 21). Here, KIT is linked to gastrointestinal stromal tumor.